| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ID: ALA5284862
Max Phase: Preclinical
Molecular Formula: C20H14N2O3
Molecular Weight: 330.34
Associated Items:
Representations
Canonical SMILES: O=C1/C(=C/c2ccc(-n3ccnc3)cc2)Cc2cc3c(cc21)OCO3
Standard InChI: InChI=1S/C20H14N2O3/c23-20-15(8-14-9-18-19(10-17(14)20)25-12-24-18)7-13-1-3-16(4-2-13)22-6-5-21-11-22/h1-7,9-11H,8,12H2/b15-7+
Standard InChI Key: DMIOBBHEMBZRQD-VIZOYTHASA-N
Associated Targets(Human)
A549 (127892 Activities)
CCD 19Lu (25 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
PANC-1 (6144 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
CTSL Tclin Cathepsin L (3852 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
CTSD Tchem Cathepsin D (3201 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Molecule Features
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
Drug Indications
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
Mechanisms of Action
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Properties
| Molecular Weight: 330.34 | Molecular Weight (Monoisotopic): 330.1004 | AlogP: 3.42 | #Rotatable Bonds: 2 |
| Polar Surface Area: 53.35 | Molecular Species: NEUTRAL | HBA: 5 | HBD: 0 |
| #RO5 Violations: 0 | HBA (Lipinski): 5 | HBD (Lipinski): 0 | #RO5 Violations (Lipinski): 0 |
| CX Acidic pKa: | CX Basic pKa: 6.05 | CX LogP: 3.28 | CX LogD: 3.26 |
| Aromatic Rings: 3 | Heavy Atoms: 25 | QED Weighted: 0.68 | Np Likeness Score: -0.71 |
References
| 1. Altıntop MD, Özdemir A, Temel HE, Demir Cevizlidere B, Sever B, Kaplancıklı ZA, Akalın Çiftçi G.. (2022) Design, synthesis and biological evaluation of a new series of arylidene indanones as small molecules for targeted therapy of non-small cell lung carcinoma and prostate cancer., 244 [PMID:36270087] [10.1016/j.ejmech.2022.114851] |
Source
Source(1):